Membrane Or Diffusion Barrier Patents (Class 424/424)
  • Patent number: 10433892
    Abstract: Provided is a material for preventing bone cement from leaking out from bone during packing of the bone cement into a bone fracture site. The bone cement can be prevented from leaking out from the bone by employing a three-dimensional structure produced from a material containing a polyhydroxyalkanoate, when packing the bone cement into the bone fracture site.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: October 8, 2019
    Assignees: National University Corporation Nagoya University, National University Corporation Nagoya Institute of Technology
    Inventors: Hitoshi Hirata, Takanobu Nishizuka, Tadahiro Natsume, Toshihiro Kasuga
  • Patent number: 10383977
    Abstract: Polymeric grafts for treating damaged biological tissue that are formed from poly(glycerol sebacate) (PGS). The PGS grafts preferably comprise a bioactive agent comprising anti-inflammatory corticosteroids, anti-oxidants, anti-thrombotic agents and anti-platelet agents. The PGS grafts can also comprise a HMG-CoA reductase inhibitor.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: August 20, 2019
    Assignee: CorMatrix Cardiovascular, Inc
    Inventor: Robert G Matheny
  • Patent number: 10301376
    Abstract: Provided are combinations, compositions and kits containing a immune globulin (IG) composition and a soluble hyaluronidase composition formulated for subcutaneous administration. Such products can be used in methods of treating IG-treatable diseases or conditions. Also provided are methods for subcutaneous administration of immune globulin whereby the dosing regimen is substantially the same as for intravenous administration of the same dosage for treatment of the same IG-treatable disease or condition.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: May 28, 2019
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Richard Schiff, Heinz Leibl
  • Patent number: 10280265
    Abstract: A method can selectively prepare a compound of formula (IV), where each R1 and each R2 are independently selected from an alkyl group, an aryl group, a halogenated alkyl group, or a halogenated aryl group of 6 to 10 carbon atoms each R3 is an alkane-diyl group, and each R4 is hydrogen or an alkyl group. The method involves hydrosilylation of an organohydrogensiloxane oligomer with a carboxylic acid alkenyl ester using an iridium complex catalyst.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: May 7, 2019
    Assignee: Dow Corning Corporation
    Inventors: Donald Eldred, Matthew Jeletic, Ryan Christopher Thomas
  • Patent number: 10272116
    Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: April 30, 2019
    Assignee: OSIRIS THERAPEUTICS, INC.
    Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
  • Patent number: 10265344
    Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: April 23, 2019
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
  • Patent number: 10245353
    Abstract: A hydrophilic electrospinning biological composite scaffold material used for tissue regeneration and a preparation method and an application thereof are provided. Fibrinogen, L-arginine or an aqueous solution of hydrochloride thereof and a P(LLA-CL) solution are blended and an electrospinning technology is used to prepare the biological composite scaffold material. The biological composite scaffold material has an equilibrium contact angle that is less than 55°, is hydrophilic and has a good application prospect in repairing body tissue defects.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: April 2, 2019
    Assignee: Shanghai P & P Biotech Co., Ltd
    Inventors: Hongbing He, Ling Su, Zhang Liu, Li Yang
  • Patent number: 10188602
    Abstract: A drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a pharmacologically active agent over an extended time period. As such, the drug delivery system finds significant utility in chronic drug administration. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods for manufacturing and using the drug delivery system are also provided.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 29, 2019
    Assignee: GESEA BIOSCIENCES INC.
    Inventors: John H. Baillie, Ruth Baillie, George Blouin, Newsha Farahani, Christopher Marx
  • Patent number: 10166128
    Abstract: The invention relates to medical devices and methods of using them. The devices are prostheses which can be percutaneously deliverable with (or on) an endovascular catheter or via other surgical or other techniques and then expanded. The prostheses are configured to have a lattice resistant to dilation and creep, which is defined by a plurality of openings. The prosthesis may also optionally have a stent disposed proximal to the lattice. In exemplary embodiments, the fluoropolymer is expanded polytetrafluoroethylene. The composite materials exhibit high elongation while substantially retaining the strength properties of the fluoropolymer membrane. In at least one embodiment, the lattice is made of a composite material that includes a least one fluoropolymer membrane including serpentine fibrils and an elastomer. A lattice including a generally tubular member formed of a composite material including a least one fluoropolymer membrane containing serpentine fibrils and an elastomer is also provided.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: January 1, 2019
    Assignee: W. L. Gore & Associates. Inc.
    Inventors: Joseph R. Armstrong, Edward H. Cully, Jeffrey B. Duncan, Mark Y. Hansen, William D. Montgomery, Wendy J. Terry
  • Patent number: 10123971
    Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 13, 2018
    Assignee: Titan Pharmaceuticals, Inc.
    Inventors: Rajesh A. Patel, Sunil R. Bhonsle
  • Patent number: 10111830
    Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: October 30, 2018
    Assignee: TITAN PHARMACEUTICALS, INC.
    Inventors: Rajesh A. Patel, Sunil R. Bhonsle
  • Patent number: 10092676
    Abstract: A biohybrid scaffold is provided that is useful in clinical applications for abdominal wall reconstruction, pelvic floor repair, breast reconstruction, as well as other soft tissue repairs. Methods of making and using the biohybrid scaffold are provided.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: October 9, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nicholas J. Amoroso, Stephen Francis Badylak, Yi Hong, Alexander Huber, Keisuke Takanari, William R. Wagner
  • Patent number: 10092672
    Abstract: An air filtration media for use with a heating ventilation and air condition (HVAC) system is provided. The filtration media comprises an air filter media layer having a first and second side, a PCO media layer having a first and second side, and a barrier layer positioned between the second side of the air filter media layer and the first side of the PCO media layer. The air filter media layer, barrier layer, and PCO layer are pleated together and enclosed within a frame for placement adjacent a light source within a plenum of the HVAC system.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: October 9, 2018
    Assignee: Lennox Industries Inc.
    Inventors: Sanjeev Hingorani, Thomas Wolowicz, Henry Greist
  • Patent number: 10092507
    Abstract: The invention relates to a metallic, nanoporous canister used to encapsulate cellular and/or biotherapeutic agents. The device is biocompatible and functions to wholly isolate a therapeutically active agent and/or cells therein. Their implantation, and survival in vivo, permits the local or systemic diffusion of their encapsulated cellular and/or biomolecular and therapeutics factors with the potential to promote repair of damaged or degenerated tissues in mammalian hosts, primarily humans.
    Type: Grant
    Filed: June 6, 2015
    Date of Patent: October 9, 2018
    Assignee: NanoVault Medical LLC
    Inventors: Willard W. Hennemann, Bryan L. Steelman, Thomas J. Webster
  • Patent number: 10092687
    Abstract: This is to provide a blood filter comprising a porous element; and a copolymer which exists in at least a part of a surface of the porous element, and which contains a recurring unit containing an organic group of the following formula (a) and a recurring unit containing an organic group of the following formula (b), wherein Ua1, Ua2, Ub1, Ub2 and Ub3, and An? are as defined in the present specification and the claims.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: October 9, 2018
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Tatsuro Kanaki, Takahiro Kishioka, Taito Nishino, Yoshiomi Hiroi, Ayako Otani, Tomoyuki Ozawa
  • Patent number: 10035917
    Abstract: A composition for the creation of a protective barrier on a wide variety of materials to prevent the deterioration and degradation caused by exposure to moisture and sun over time.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: July 31, 2018
    Inventor: David Walden
  • Patent number: 10016464
    Abstract: The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta. In certain embodiments, the composition comprises amniotic membrane powder or solubilized amniotic membrane (SAM). In some aspects, the composition is cell-free and rich in cytokines, extracellular matrix proteins, and other components that improve tissue regeneration. In one aspect, the composition is a hydrogel scaffold that comprises amniotic membrane. The present invention reduces contraction and improves blood vessel development in regenerating tissue.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: July 10, 2018
    Assignee: Wake Forest University Health Sciences
    Inventors: Sean V. Murphy, Aleksander Skardal, Anthony Atala
  • Patent number: 9931116
    Abstract: A tissue buttress is provided on at least a first and second jaw of a surgical stapling apparatus. The tissue buttress comprises an electrophilic component and a nucleophilic component. At least a portion of the tissue buttress may be disposed within either or both of the staple pockets and staple forming pockets, securing the tissue buttress to at least one of the staple jaws.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: April 3, 2018
    Assignee: COVIDIEN LP
    Inventors: Danyel Racenet, Steven L. Bennett, Erik Carlson, Kenneth H. Whitfield, Gregg Krehel
  • Patent number: 9883944
    Abstract: A surgical implant, which in use, provides a barrier between layers of tissue such that tissue on one side of the implant does not adhere to tissue on the other side, the implant being made of suitably anatomically shaped surgically acceptable sheet material.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: February 6, 2018
    Assignee: SCIMOTANA PTY LTD
    Inventors: Andrew Batty, Paul D'Urso
  • Patent number: 9795573
    Abstract: A multi-step stabilization method for connective tissue is described. Stabilized tissues can exhibit increased resistance to degradation due to enzyme activity, fatigue and storage. The multi-step method includes a first step during which the tissue can be incubated with a glycosaminoglycanase inhibitor such as a sulfated oligosaccharide, one example of which being neomycin, a second step during which the tissue can be incubated with a crosslink activator such as a carbodiimide crosslink activator and/or a crosslinking agent such as a heterobifunctional crosslinking agent and/or a phenolic compound such as a tannin, examples of which include tannic acid and pentagalloylglucose, and a third step during which the tissue can be incubated with a second crosslink activator that can be the same or different as the first crosslink activator.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: October 24, 2017
    Assignee: Clemson University
    Inventors: Naren Vyavahare, Hobey Tam
  • Patent number: 9795679
    Abstract: Simple mixing/blending of a special class of drug-depot forming tri-block copolymers polymers, with the opportunity to cost-effectively tailor drug delivery performances of such biodegradable, injectable depots in a clinical and an industrial setting. How to visualize these depots for various imaging related purposes is described.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: October 24, 2017
    Assignee: INGELL TECHNOLOGIES HOLDING B.V.
    Inventors: Audrey Petit, Peter Bruin, Mike De Leeuw, Ronald Meijboom
  • Patent number: 9697332
    Abstract: Methods and systems for providing therapy related data management are provided. The subject systems include one or more device components, and at least one memory storage unit and at least one data storage unit associated with such one or more device components. The device components may include one or more of an analyte monitoring system, a fluid delivery device and a remote terminal. The subject methods include use of the subject systems to optimize treatment of a patient.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: July 4, 2017
    Inventor: R. Curtis Jennewine
  • Patent number: 9670447
    Abstract: The present disclosure is directed to embodiments of microstructured membranes, methods of fabricating microstructured membranes, bioreactors housing microstructured membranes, and methods of using bioreactors and microstructured membranes. In some embodiments, the present disclosure allows culturing of cellular tissues in an environment which more accurately resembles a native environment. In some more specific embodiments, the present disclosure allows culturing of tumor cells on a membrane having a microfabricated pattern which mimics a native vasculature system.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: June 6, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Chandan Das, Ashley A. Jaeger, Thomas J. Pohida, Michael M. Gottesman, Randall H. Pursley, Philip G. McQueen, Nicole Y. Morgan
  • Patent number: 9656001
    Abstract: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: May 23, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Sarah Mayes, Christine E. Schmidt
  • Patent number: 9622777
    Abstract: A surgical access assembly and method of use is disclosed. The surgical access assembly comprises an outer sheath and an obturator. The outer sheath and obturator are configured to be delivered to an area of interest within the brain. Either the outer sheath or the obturator may be configured to operate with a navigational system to track the location of either within the brain. Once positioned at a desired location, the obturator is removed, leaving a distal end of the outer sheath adjacent an area of interest, and creating a working corridor. Interventional devices may be introduced to the area of interest, as well as a variety of treatments. A subsequent treatment process may also be employed.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: April 18, 2017
    Assignee: Nico Corporation
    Inventors: Joseph L. Mark, Amin Kassam
  • Patent number: 9611353
    Abstract: Novel pentablock polymers having a PCL-PLA-PEG-PLA-PCL or PCL-PGA-PEG-PGA-PCL configuration, wherein PEG is polyethylene glycol, PCL is poly(8-caprolactone), PGA is poly(glycolic acid), and PLA is poly(lactic acid), and methods of making nanoparticles from the pentablock polymers, are disclosed. The invention is also directed to a method for preparing nanoparticle compositions comprised of polymers with high levels of bioactive or diagnostic agents.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: April 4, 2017
    Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI
    Inventors: Ashim K. Mitra, Sulabh P. Patel, Ravi D. Vaishya, Vibhuti Agrahari
  • Patent number: 9572889
    Abstract: The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: February 21, 2017
    Assignee: Intarcia Therapeutics, Inc.
    Inventors: Thomas R. Alessi, Karling Alice Leung, Ryan D. Mercer, Cristina G. Negulescu, Catherine M. Rohloff, Bing Yang
  • Patent number: 9498156
    Abstract: A sensor (e.g., an optical sensor) that may be placed within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid) within the animal. The sensor may include a sensor housing and a polymer graft including indicator molecules and covering at least a portion of the sensor housing. The opacity of the polymer graft may remain substantially the same (i.e., may have little or no variation) over time. The sensor may include a photodetector, and variation in the opacity of the polymer graft does not cause a significant change in a measurement signal output by the photodetector. The polymer hydrogel may be made of polymers including acrylic acid and/or polyethylene glycol.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: November 22, 2016
    Assignee: Senseonics, Incorporated
    Inventors: Todd Whitehurst, Philip Huffstetler
  • Patent number: 9481865
    Abstract: Disclosed is a serum-free freezing medium used in adipose-derived stem cells and a method for establishing an adipose-derived stem cell library. The serum-free freezing medium comprises a serum-free culture medium, dimethyl sulfoxide and a serum substitution component KSR; the defects of unstable freezing quality of the adipose-derived stem cells and influence of harmful factors in serum on the adipose-derived stem cells are solved, and the adipose-derived stem cells stored have the advantages of high survival percentage, well adherence growth and strong differentiation capacity.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: November 1, 2016
    Assignees: Cellular Biomedicine Group (Shanghai) Ltd, Cellular Biomedicine Group (Wuxi) Ltd
    Inventors: Helen Zhang, Luyi Zhang, Wei Cao
  • Patent number: 9452083
    Abstract: A bioresorbable drug eluting intravitreal implant system includes a syringe with a chamber containing a medicinal drug. A balloon is releasably secured to a needle where the needle has a central section chamber in fluid communication with a chamber in the syringe. The needle central section has an opening formed through a wall for transporting the medicinal drug to the interior of the balloon subsequent to insertion of the needle through the sclera of a patient's eye.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: September 27, 2016
    Assignee: Drug Delivery Company, LLC
    Inventors: Jeffrey D. Benner, Steven M. Cohen
  • Patent number: 9446168
    Abstract: A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: September 20, 2016
    Assignee: Beta-O2 Technologies Ltd.
    Inventors: Uriel Barkai, Avi Rotem, Yehezkel Bremer, Tova Neufeld
  • Patent number: 9446226
    Abstract: Composite structures composed of a fibril core and a polymeric coat and designed capable of encapsulating both hydrophobic and hydrophilic bioactive agents while retaining the activity of these agents are disclosed. Further disclosed are processes of preparing such composite structures, and medical devices and disposable articles made therefrom.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: September 20, 2016
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventor: Meital Zilberman
  • Patent number: 9445941
    Abstract: A bioresorbable drug eluting intravitreal implant system includes a syringe with a chamber containing a medicinal drug. A balloon is releasably secured to a needle where the needle has a central section chamber in fluid communication with a chamber in the syringe. The needle central section has an opening formed through a wall for transporting the medicinal drug to the interior of the balloon subsequent to insertion of the needle through the sclera of a patient's eye.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: September 20, 2016
    Assignee: Drug Delivery Company, LLC
    Inventors: Jeffrey D. Benner, Steven M. Cohen
  • Patent number: 9408986
    Abstract: A method of purifying at least one of THC and CBD from a cannabis-containing composition includes heating the cannabis-containing composition to a temperature sufficient to volatilize at least one of THC and CBD into a vapor and condensing the vapor on a substrate. A drug delivery cartridge includes a substrate coated with at least one of THC and CBD and configured to allow for passage of air through the cartridge to volatilize at least one of THC and CBD for inhalation by a user to induce a medicinal or therapeutic effect to the user.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: August 9, 2016
    Inventor: Timothy McCullough
  • Patent number: 9393272
    Abstract: Microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: July 19, 2016
    Assignee: Wake Forest University Health Sciences
    Inventors: Emmanuel C. Opara, Benjamin S. Harrison
  • Patent number: 9387068
    Abstract: A self-sealing shell useful as a component of a soft fluid-filled prosthetic implant is provided. The shell is at least partly constructed of a wall made of a colloid of an elastomeric polymer matrix and particles of a water-swellable material distributed therein.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: July 12, 2016
    Assignee: Allergan, Inc.
    Inventor: David Schuessler
  • Patent number: 9387279
    Abstract: A biocompatible insulin delivery device is provided comprising an insulin reservoir sealed with a glucose-responsive plug or membrane. The plug functions to release insulin from the reservoir in response to a hyperglycemic glucose concentration and to prevent insulin release from the reservoir in response to hypoglycemic glucose concentration. In one embodiment, the plug is made of a biocompatible polymeric matrix comprising an inorganic component, a stimulus-responsive component and a catalytic component.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: July 12, 2016
    Assignee: The Governing Council of the University of Toronto
    Inventors: Xiao Yu Wu, Kai Zhang, Huiyu Huang, Claudia Gordijo, Jason Siu-Wei Li, Michael K.L. Chu
  • Patent number: 9364427
    Abstract: The invention provides a device for Encapsulated Cell Therapy. The device includes an implantable capsule containing cells which secrete a biologically active compound for providing a biological function. The capsule has a semi permeable outer membrane for delivery of the compound e.g. at a site in the central nervous system or the spinal cord, e.g. in the brain of a patient. The capsule is connected to a tether which e.g. facilitates removal of the capsule from the patient. To facilitate insertion of the capsule into the patient, a stiffener may be attached to the tether to make the tether more rigid. The invention further provides a container for storing a cell therapy device and a method of locating the device in the body of a patient.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: June 14, 2016
    Assignee: NsGene A/S
    Inventors: Lars U. Wahlberg, Jens Tornøe
  • Patent number: 9358320
    Abstract: Embodiments of the present invention encompass anti-adhesion wound dressings including patches made from amnion tissue obtained from human birth tissue. Exemplary amnion patches can be fabricated by folding a section of amnion over on itself with the epithelial layer on the outside of the folded patch and the fibroblast layer on the inside of the folded patch. Optionally, individual amnion tissue pieces can be sandwiched together to provide a multi-layer patch. Sufficient pressure is applied to the layered amnion to cause adherence between opposing faces of the fibroblast layers. The pressed fibroblast layers provide mechanical strength to hold the amnion patch together with the epithelial layers on the outsides of the amnion patch.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: June 7, 2016
    Assignee: AlloSource
    Inventors: Adrian C. Samaniego, Ross M. Wilkins
  • Patent number: 9351924
    Abstract: One aspect of the present invention relates to a drug delivery system comprising a layered structure where a drug layer and a biodegradable polymer layer for controlling the release of drugs are alternately laminated. The drug delivery system can easily control an in-vivo drug release rate and a release amount.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: May 31, 2016
    Assignee: SNU R&DB FOUNDATION
    Inventors: Dong-Il Cho, Seok Jun Hong, Sang Min Lee, Jae Hyun Ahn, Hyoung Jung Yoo
  • Patent number: 9308295
    Abstract: An improved composition for inducing bone growth is provided that is a mixture of DBM and a perfluorocarbon oxygen carrier. Injection/implantation of a composition of DBM and a perfluorocarbon results in enhancement of bone formation.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: April 12, 2016
    Assignee: THERACELL, INC.
    Inventors: Andrew J. Carter, Nelson L. Scarborough, Richard K. Grant, Frank M. Phillips, Stephen H. Hochschuler
  • Patent number: 9301926
    Abstract: Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 ?m to about 1000 ?m, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: April 5, 2016
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Laura Indolfi, Elazer R. Edelman, Robert S. Langer, Jeffrey W. Clark, David T. Ting, Cristina Rosa Annamaria Ferrone, Matteo Ligorio
  • Patent number: 9226998
    Abstract: A method for producing a drug delivery system provides a member including a combination of a drug substance and a polymer or other material; and forms a layer on a surface of the combination using gas cluster ion beam irradiation, which layer determines a release rate for the drug substance, wherein the layer is an encapsulating layer formed by densifying or carbonizing components of the drug or of the polymer or of the other material by the gas cluster ion beam irradiation.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: January 5, 2016
    Assignee: Exogenesis Corporation
    Inventors: Stephen M. Blinn, Richard C. Svrluga
  • Patent number: 9211274
    Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of a TRPV1 compound (e.g., capsaicinoid compound) at or near a target site, one can relieve pain caused by diverse sources, including but not limited to, postoperative pain, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: December 15, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Nicholas A. Moore, Danielle L. Clay
  • Patent number: 9175153
    Abstract: The present invention provides cellulose hydrogels having one or more of the following properties: high water content, high transparency, high oxygen permeability, high biocompatibility, high tensile strength and desirable thermal stability. The present invention further provides a process for preparing a cellulose hydrogel comprising (i) a step of activating cellulose, in which the activating step comprises contacting the cellulose with a solvent to activate the cellulose for a time duration from about 2 hours to about 30 hours; (ii) substantially dissolving the activated cellulose to form a solution; and (iii) gelling the solution to form a gel, in which the gelling step comprises allowing the solution to gel in an environment comprising a relative humidity from about 30% to about 80% at 35° C.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: November 3, 2015
    Assignee: The Johns Hopkins University
    Inventors: Morgana M. Trexler, Jenna L. Graham, Jennifer L. Breidenich, Jeffrey P. Maranchi, Julia B. Patrone, Marcia W. Patchan, Jennifer H. Elisseeff, Xiomara Calderon-Colon
  • Patent number: 9127082
    Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: September 8, 2015
    Assignee: HERANTIS PHARMA PLC.
    Inventors: Mart Saarma, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen
  • Patent number: 9040111
    Abstract: A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: May 26, 2015
    Assignees: JAPAN STENT TECHNOLOGY CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEM, TOYO ADVANCED TECHNOLOGIES CO., LTD.
    Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
  • Patent number: 9034363
    Abstract: A method for delivering at least one drug at a target site in a blood vessel for treating at least one of an acute myocardial infarction, a thrombus containing lesion and a saphenous-vein graft lesion is disclosed. The method includes delivering nano-carriers at the target site. The nano-carriers include one or more drugs encapsulated with a first biological agent. The nano-carriers further include a second biological agent in contact with one or more of the first biological agent and the one or more drugs. The first biological agent and the second biological agent have a first dissolution rate and a second dissolution rate respectively. The first dissolution rate is different from the second dissolution rate. The one or more drugs are released at the target site from the nano-carriers at a first release rate and a second release rate in response to dissolution of the first biological agent and the second biological agent, respectively.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: May 19, 2015
    Assignee: CONCEPT MEDICAL RESEARCH PRIVATE LIMITED
    Inventors: Manish Doshi, Divyesh Sherdiwala, Prakash Sojitra
  • Patent number: 9017711
    Abstract: Compositions and methods for treating and healing injured soft tissues such as tendons and ligaments are provided. The composition may be a wrap comprising human collagen in the form of a sheet. The human collagen has been processed so that is retains proteins that are associated with it in its natural state. The sheet may optionally be coated on one or more sides with one or more of additional human collagen, therapeutic agents, additional soft tissue growth factors or hydroxyapatite.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: April 28, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Nels J. Lauritzen, Abdulhafez A. Selem, Lawrence A. Shimp, Hsiu Ying Sherry Wang
  • Patent number: 9011899
    Abstract: Devices and methods for transplanting cells in a host body are described. The cell comprises a porous scaffold that allows ingrowth of vascular and connective tissues, a plug or plug system configured for placement within the porous scaffold, and a seal configured to enclose a proximal opening in the porous scaffold. The device may further comprise a cell delivery device for delivering cells into the porous scaffold. The method of cell transplantation comprises a two step process. The device is incubated in the host body to form a vascularized collagen matrix around a plug positioned within the porous scaffold. The plug is then retracted from the porous scaffold, and cells are delivered into the vascularized space created within the porous scaffold.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: April 21, 2015
    Assignee: Sernova Corporation
    Inventors: Craig Hasilo, Justin Leushner, Daniel Nicholas Haworth, Simon Shohet, Philip Michael Toleikis, Delfina Maria Mazzuca Siroen